Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

11.48 -0.24 (-2.05%)
Streaming Delayed Price Updated: 11:39 AM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
News headline image
Emergent Secures Contract To Manufacture Providence Therapeutics' COVID-19 Vaccine Candidate ↗
Emergent BioSolutions Inc (NYSE: EBS) has signed a five-year agreement with Providence Therapeutics valued at about $90 million to develop and... 
Via Benzinga
News headline image
Moderna Withdraws 1.6M COVID-19 Vaccine Doses In Japan Over Contamination Concerns ↗
More than a million doses of Moderna Inc’s (NASDAQ: MRNA) coronavirus vaccine have been taken out of circulation in Japan after reports of contamination emerged, Nikkei Asia... 
Via Benzinga
News headline image
Emergent BioSolutions' COVID-19 Plasma Candidate To Be Tested As Outpatient Treatment ↗
Emergent BioSolutions Inc (NYSE: EBS) has announced the initiation of a Phase 3 trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous... 
Via Benzinga
News headline image
NYSE:EBS Long Term Investor Alert: Investigation of Potential Wrongdoing at Emergent BioSolutions Inc ↗
San Diego, CA -- (SBWIRE) -- 08/23/2021 -- Certain directors of Emergent BioSolutions Inc are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Topics Lawsuit
News headline image
Emergent BioSolutions inc (EBS) Q2 2021 Earnings Call Transcript ↗
EBS earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Emergent BioSolutions Stock Higher As COVID-19 Vaccine Production To Resume At Baltimore Plant ↗
Emergent BioSolutions Inc (NYSE: EBS) will resume production of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine at its troubled Baltimore... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
News headline image
These Companies Have Seen Large Returns From 2020 Government Investment ↗
Much focus on investment comes from the private sector, particularly those of the venture capitalist persuasion. But one of the biggest investors this country has is the federal... 
Via Benzinga
News headline image
FDA Releases More JNJ's COVID-19 Vaccine Substance From Baltimore Plant ↗
Federal regulators on Friday 
Via Benzinga
News headline image
Can Emergent BioSolutions Recover From Its Recent Blunders? ↗
Yes, but it probably won't be an easy path. 
Via The Motley Fool
News headline image
Moderna's COVID-19 Vaccine Produced Neutralizing Titers Against All Variants Tested ↗
Moderna Inc (NASDAQ: MRNA) has announced new results from in vitro neutralization studies of sera from individuals vaccinated with its COVID-19 vaccine. The COVID-... 
Via Benzinga
News headline image
A Look Into Healthcare Sector Value Stocks ↗
What is a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
News headline image
Faruqi & Faruqi, LLP is Investigating Emergent BioSolutions (EBS) on Behalf of its Shareholders
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
5 Value Stocks To Watch In The Healthcare Sector ↗
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... 
Via Benzinga
News headline image
FINAL DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
MONDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Two Days Left to Actively Participate in Emergent BioSolutions Inc. (EBS) Class Action: Bronstein, Gewirtz & Grossman, LLC
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Kessler Topaz Meltzer & Checker, LLP:  Final Deadline Reminder for Emergent BioSolutions Inc. Investors – EBS
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
News headline image
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Emergent BioSolutions, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
FRIDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
FRIDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
FRIDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
FDA Authorizes 10M JNJ COVID-19 Vaccine Doses, Asks To Discard 60M From Emergent Plant: NYT ↗
The FDA has asked Johnson & Johnson (NYSE: JNJ) to discard 60 million doses of its COVID-19 vaccine manufactured at the troubled Emergent BioSolutions Inc... 
Via Benzinga
News headline image
7-DAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Entwistle & Cappucci LLP Announces It Has Filed a Securities Class Action Against Emergent BioSolutions Inc. (NYSE: EBS)
From Entwistle & Cappucci LLP
Via Business Wire
News headline image
AstraZeneca Seeks Switching COVID-19 Vaccine Production to Catalent Plant: NYT ↗
AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc’s (... 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.